Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Journal of the National Cancer Institute - 16 Mar 2011

Lash Timothy L, Cronin-Fenton Deirdre, Ahern Thomas P, Rosenberg Carol L, Lunetta Kathryn L, Silliman Rebecca A, Garne Jens Peter, Sørensen Henrik Toft, Hellberg Ylva, Christensen Mariann, Pedersen Lars, Hamilton-Dutoit Stephen

Abstract excerpt

BACKGROUND: Cytochrome P450 2D6 (CYP2D6) inhibition reduces the concentration of 4-hydroxylated tamoxifen metabolites, but the clinical relevance remains uncertain. METHODS: We conducted a large case-control study nested in the population of 11 251 women aged 35-69 years at diagnosis of stage I-III breast cancer between 1985 and 2001 on Denmark's Jutland Peninsula and registered with the Danish Breast Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Confounding Factors, Epidemiologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Denmark

Share to Medication Adherence

Share to Monte Carlo Method

Share to Receptors, Estrogen

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 21325141
DOI: 10.1093/jnci/djr010
PMCID: PMC3057982

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.PMID 21325141Read ↗

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.Semantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.Semantic proximity Read ↗

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.Semantic proximity Read ↗

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.